Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEXIS
- 21 Jun 2017 Planned End Date changed from 1 May 2022 to 1 Jun 2022.
- 21 Jun 2017 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.
- 21 Jun 2017 Status changed from not yet recruiting to recruiting.